Novel Radiopharmaceuticals for Therapy

Guidoccio, Federica; Mazzarri, Sara; Depalo, Tommaso; Orsini, Federica; Erba, Paola Anna; Mariani, Giuliano

doi:10.1007/978-3-031-05494-5_36

Cited by 1 publication

(1 citation statement)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite their utility, the use of 18 F-labeled compounds is often constrained by significant production costs and a short half-life [25]. In contrast, single-photon emission computed tomography (SPECT), which is widely adopted across many nuclear medicine facilities, has seen significant advancements with the development of radioiodinated and [ 99m Tc]-labeled radiopharmaceuticals targeting solid tumors [26][27][28][29]. These novel agents aim to optimize tumor imaging by enhancing tumor uptake, target-to-non-target (T/NT) ratios, and target-to-blood (T/B) ratios [30].…”

Section: Tumor Imaging With Radiotracersmentioning

confidence: 99%

Radiological and Molecular Analysis of Radioiodinated Anastrozole and Epirubicin as Innovative Radiopharmaceuticals Targeting Methylenetetrahydrofolate Dehydrogenase 2 in Solid Tumors

Binmujlli

2024

Pharmaceutics

View full text Add to dashboard Cite

In the dynamic field of radiopharmaceuticals, innovating targeted agents for cancer diagnosis and therapy is crucial. Our study enriches this evolving landscape by evaluating the potential of radioiodinated anastrozole ([125I]anastrozole) and radioiodinated epirubicin ([125I]epirubicin) as targeting agents against MTHFD2-driven tumors. MTHFD2, which is pivotal in one-carbon metabolism, is notably upregulated in various cancers, presenting a novel target for radiopharmaceutical application. Through molecular docking and 200 ns molecular dynamics (MD) simulations, we assess the binding efficiency and stability of [125I]anastrozole and [125I]epirubicin with MTHFD2. Molecular docking illustrates that [125I]epirubicin has a superior binding free energy (∆Gbind) of −41.25 kJ/mol compared to −39.07 kJ/mol for [125I]anastrozole and −38.53 kJ/mol for the control ligand, suggesting that it has a higher affinity for MTHFD2. MD simulations reinforce this, showing stable binding, as evidenced by root mean square deviation (RMSD) values within a narrow range, underscoring the structural integrity of the enzyme–ligand complexes. The root mean square fluctuation (RMSF) analysis indicates consistent dynamic behavior of the MTHFD2 complex upon binding with [125I]anastrozole and [125I]epirubicin akin to the control. The radius of gyration (RG) measurements of 16.90 Å for MTHFD2-[125I]anastrozole and 16.84 Å for MTHFD2-[125I]epirubicin confirm minimal structural disruption upon binding. The hydrogen bond analysis reveals averages of two and three stable hydrogen bonds for [125I]anastrozole and [125I]epirubicin complexes, respectively, highlighting crucial stabilizing interactions. The MM-PBSA calculations further endorse the thermodynamic favorability of these interactions, with binding free energies of −48.49 ± 0.11 kJ/mol for [125I]anastrozole and −43.8 kJ/mol for MTHFD2-. The significant contribution of Van der Waals and electrostatic interactions to the binding affinities of [125I]anastrozole and [125I]epirubicin, respectively, underscores their potential efficacy for targeted tumor imaging and therapy. These computational findings lay the groundwork for the future experimental validation of [125I]anastrozole and [125I]epirubicin as MTHFD2 inhibitors, heralding a notable advancement in precision oncology tools. The data necessitate subsequent in vitro and in vivo assays to corroborate these results.

show abstract

Section: Tumor Imaging With Radiotracersmentioning

confidence: 99%

Radiological and Molecular Analysis of Radioiodinated Anastrozole and Epirubicin as Innovative Radiopharmaceuticals Targeting Methylenetetrahydrofolate Dehydrogenase 2 in Solid Tumors

Binmujlli

2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Novel Radiopharmaceuticals for Therapy

Cited by 1 publication

References 134 publications

Radiological and Molecular Analysis of Radioiodinated Anastrozole and Epirubicin as Innovative Radiopharmaceuticals Targeting Methylenetetrahydrofolate Dehydrogenase 2 in Solid Tumors

Radiological and Molecular Analysis of Radioiodinated Anastrozole and Epirubicin as Innovative Radiopharmaceuticals Targeting Methylenetetrahydrofolate Dehydrogenase 2 in Solid Tumors

Contact Info

Product

Resources

About